化合物 Loxoprofen sodium (dihydrate),Loxoprofen sodium (dihydrate)

化合物 Loxoprofen sodium (dihydrate)|T60704|TargetMol

價格	￥13800	￥17500	￥10600
包裝	50mg	100mg	25mg

最小起訂量	25mg
發(fā)貨地	上海
更新日期	2026-04-02

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 Loxoprofen sodium (dihydrate)	英文名稱:Loxoprofen sodium (dihydrate)
CAS:226721-96-6	品牌: TargetMol
產(chǎn)地: 美國	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
產(chǎn)品類別: 抑制劑
貨號: T60704

Product Introduction

Bioactivity

名稱	Loxoprofen sodium (dihydrate)
描述	Loxoprofen sodium dihydrate is a non-steroidal, orally active anti-inflammatory agent that has analgesic and anti-pyretic properties. Loxoprofen sodium dihydrate exhibits antitumor activity which also can reduce atherosclerosis. Loxoprofen sodium dihydrate is a nonselective inhibitor of COX with IC 50 s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively [1] [2] [3] [4].
體外活性	Loxoprofen sodium dihydrate, an anti-inflammatory prodrug (NSAID), is a nonselective COX inhibitor with IC 50 s of 6.5 and 13.5 μM for COX-1 and COX-2 in human whole blood assays, respectively [1]. Loxoprofen (LOX) sodium dihydrate is a non-selective cyclooxygenase inhibitor that is widely used for the reasearch of pain and inflammation caused by chronic and transitory conditions. Its alcoholic metabolites are formed by carbonyl reductase (CR) and they consist of trans-LOX, which is active, and cis-LOX, which is inactive. In addition, LOX sodium dihydrate can also be converted into an inactive hydroxylated metabolite (OH-LOXs) by cytochrome P450 (CYP) [2].
體內(nèi)活性	Loxoprofen sodium (4 mg/kg/day; p.o.; 1 or 8 weeks) dihydrate reduces atherosclerosis in mice by reducing inflammation [3]. Loxoprofen sodium (60 μg/mL; p.o.; 24 days) dihydrate suppresses mouse tumor growth by inhibiting VEGF [4]. Animal Model: ApoE -/- mice (C57BL/6J-Apoe tm1Unc ) with high-fat diet (0.2% cholesterol, 21% saturated fat) from 8 to 16 weeks of age [3] Dosage: 4 mg/kg/day in drinking water Administration: Oral dosing from 8 to 16 weeks of age or from 15 to 16 weeks of age Result: Inhibited platelet thromboxane production and platelet aggregation. Reduced extent of atherosclerosis. Suppressed the production of PGE 2, TxB 2 and PGI 2. Animal Model: 6-week-old male C57BL/6 and BDF1 mice, 100 μL suspensions (2 × 10 6 cells/mL) of LLC cells and KLN205 cells were injected subcutaneously into C57BL/6 and BDF1 mice, respectively [4]. Dosage: 60 μg/mL Administration: Oral dosing in drinking water, every day for 24 days Result: Suppressed tumor growth and angiogenesis, suppressed expression of VEGF in mice with LLC tumor, inhibited tubular formation of HUVECs.
存儲條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.
相關(guān)產(chǎn)品	Trometamol \| Gallic Acid Monohydrate \| Naproxen sodium \| 4-Aminosalicylic acid \| 5-Methylfurfural \| Phenylbutazone \| Indomethacin \| Paradol \| Acetaminophen \| Diclofenac Potassium \| Magnesium sulfate \| Phenidone

關(guān)鍵字： Loxoprofen sodium (dihydrate)|TargetMol

公司簡介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個國家和地區(qū)，已發(fā)展成為全球知名的化合物庫和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學試劑盒等，此外，我們還建設(shè)有CADD（計算機輔助藥物設(shè)計）研究中心、藥理實驗室、藥化合成平臺三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （14年）	注冊資本	566.265100萬人民幣
員工人數(shù)	100-500人	年營業(yè)額	￥ 1億以上
主營行業(yè)	天然產(chǎn)物,生化試劑,分子生物學,分子砌塊,生物技術(shù)服務(wù)	經(jīng)營模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國（陶術(shù)生物）

VIP 5年

公司成立：14年
注冊資本：566.265100萬人民幣
企業(yè)類型：有限責任公司(自然人投資或控股)
主營產(chǎn)品：小分子抑制劑、藥物篩選化合物庫、藥物篩選等
公司地址：靜安區(qū)江場三路238號8樓

進入店鋪

詢盤

店內(nèi)推薦

化合物 AZD9496|T3975|TargetMol

詢價

化合物 cis-Nerolidol|T78486|TargetMol

￥5690

阿義馬林|T4550|TargetMol

￥119